dasatinib pharos 50 mg filmtabletta
sandoz hungária kft. - dasatinib -
dasatinib pharos 70 mg filmtabletta
sandoz hungária kft. - dasatinib -
dasatinib pharos 100 mg filmtabletta
sandoz hungária kft. - dasatinib -
dasatinib pharos 140 mg filmtabletta
sandoz hungária kft. - dasatinib -
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
daruph 16 mg filmtabletta
zentiva, k.s. (csehország) - dasatinib -
daruph 40 mg filmtabletta
zentiva, k.s. (csehország) - dasatinib -
daruph 55 mg filmtabletta
zentiva, k.s. (csehország) - dasatinib -
daruph 63 mg filmtabletta
zentiva, k.s. (csehország) - dasatinib -
daruph 79 mg filmtabletta
zentiva, k.s. (csehország) - dasatinib -